Download PDF
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2006; 27(03): 27-34
DOI: 10.1055/s-0041-1733173
Original Article

How i treat myeloma?

Tapan Saikia
Consultant Medical Oncologist, Prince Aly Khan Hospital Nesbit Road, Mazagaon Mumbai 400010, India
› Author Affiliations
› Further Information
  PDF Download Permissions and Reprints


Publication History

Article published online:
23 March 2022

© 2006. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Kyle R, Rajkumar SV. Multiple myeloma. N Engl J Med 2004;351:1860-73.
  • 2 Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Blade J, et al. International staging system for multiple myeloma. J Clin Oncol 2005;23:3412-20.
  • 3 International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 2003;121:749-57.
  • 4 Roodman GD. Role of the bone marrow microenvironment in multiple myeloma. J Bone Min Res 2002;17:624-27.
  • 5 Roodman GD. Mechanism of bone metastasis. N Engl J Med 2004;350:1655-64.
  • 6 Greipp PR, Lust JA, O'Fallon WM, et al. Plasma cell labeling index and b-2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma. Blood 1993;81:3382-7.
  • 7 Barlogie B, Smallwood L, Smith T, Alexanian R. High serum levels of LDH identify a high-grade lymphomalike myeloma. Ann Int Med 1989;110:521-5.
  • 8 Fonseca R, Barlogie B, Battaille R, et al. Genetics and cytogenetics of multiple lyeloma: a workshop report. Cancer Res 2004;64:1546-58.
  • 9 Fonseca R, Debes-Marun CS, Pickem EB, et al. The recurrent IgH translocations are highly associated with non-hyperdiploid variant of multiple myeloma. Blood 2003;102:2562-7.
  • 10 Bergsagel PL, Kuehl WM, Zhan F, et al. Cyclin D expression and early and unifying pathogenetic event in multiple myeloma. Blood 2005;106:296-303.
  • 11 Zhan F, Hardin J, Kordmeier B, et al. Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood 2002;99:1745-57.
  • 12 Child JA, Morgan GJ, Davies FE, et al. High-dose chemotherapy with hematopoietic stem cell rescue for multiple myeloma. N Engl J Med 2003;8:1875-83.
  • 13 Kumar L, Raju GM, Ganessan K, et al. High dose chemotherapy followed by haemopietic stem cell transplant in multiple myeloma. Natl Med J India 2003;16:16-21.
  • 14 Attal M, Harousseau J-L, Facon T, et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 2003;349:2495-2502.
  • 15 Palumbo A, Rus C, zeldis JB, Rodeghiers F, Boccadoro M, et al, The Italian multiple myeloma network,GIMEMA. Enoxaparine or aspirin for the prevention of recurrent thromboembolism in newly diagnosed myeloma patients treated with melphalan and prednisone plus thalidomide or lenalidomide. J Thromb Haemost 2006;4:1842-5.
  • 16 Rajkumar SV, Blood E, Vesole D, et al. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncologic Group. J Clin Oncol 2006;24:431- 6.
  • 17 Cavo M, Zamagni E, Tosi P, et al. Superiority of thalidomide and dexamethasone over vincristinedoxorubicin- dexamethasone (VAD) as primary therapy in preparation for autologous transplantation multiple myeloma. Blood 2005;106:35-9.
  • 18 Barlogie B, Desikan R, Eddelmon P, et al. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood 2001;98:492-4.
  • 19 Bladé J, Sureda JM, Ribera J, et al. High-dose therapy autotransplantation intensification versus continued conventional chemotherapy in multiple myeloma patients responding to initial chemotherapy: results of a prospective randomized trial from the Spanish cooperative group PETHEMA. Hematol J 2003;4:S56.
  • 20 Durie BG, Harousseau J-L, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia 2006;doi:10.1038/sj.leu.2404284 (Epub ahead of print).
  • 21 Richardson PG, Barlogie B, BerensonJ, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003;348:2609-17.
  • 22 Richardson PG, Sonnelveld P, Schuster MW, et al. Bortezomib or high dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005;352:2487-98.
  • 23 San Miguel J, Blade J, Boccadoro M, et al. A practical update on the use of bortezomib in the management of multiple myeloma. Oncologist 2006;11:51-61.
  • 24 de Weerdt O, van de Donk NW, Veth G, et al. Continuous low-dose cyclophosphamide-prednisolone is effective and well tolerated in patients with advanced mulptiple myeloma. Net J Med 2001;59:50-56.
  • 25 Garcia-Sanz R, Gonzalez-Porras JR, Hernandez JM, et al. The oral combination of thalidomide cyclophosphamide and dexamethasone (thalCydex) is effective in relapsed/refractory multiple myeloma. Leukemia 2004;18:856-63.
  • 26 Richardson PG, Blood E, Mitsiades CS, et al. A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood 2006 Jul 18 (Epub ahead of print).
  • 27 Palumbo A, Bringhen S, Caravita T, et al. Oral MP chemotherapy plus thalidomide compared with MP alone in elderly patients with multiple myeloma: results of a randomised controlled trial. Lancet 2006;367:825- 31.
  • 28 Facon T, Mary JY, Hulin C, et al. Randomized clinical trial comparing melphalan-prdnisone (MP), MPthalidomide (MP-THAL) and high dose therapy using melphalan 100 mg/m2 (MEL 100) for newly diagnosed myeloma patients aged 65-75 years. Interim anakysis of the IFM 99-06 trial on 350 patients. Blood 2004;104:63a.